|
1
|
de Vries BM, Golla SSV, Zwezerijnen GJC, Hoekstra OS, Jauw YWS, Huisman MC, van Dongen GAMS, Menke-van der Houven van Oordt WC, Zijlstra-Baalbergen JJM, Mesotten L, Boellaard R, Yaqub M. 3D Convolutional Neural Network-Based Denoising of Low-Count Whole-Body 18F-Fluorodeoxyglucose and 89Zr-Rituximab PET Scans. Diagnostics (Basel) 2022; 12:diagnostics12030596. [PMID: 35328149 PMCID: PMC8946936 DOI: 10.3390/diagnostics12030596] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2022] [Revised: 02/22/2022] [Accepted: 02/24/2022] [Indexed: 11/23/2022] Open
Abstract
Acquisition time and injected activity of 18F-fluorodeoxyglucose (18F-FDG) PET should ideally be reduced. However, this decreases the signal-to-noise ratio (SNR), which impairs the diagnostic value of these PET scans. In addition, 89Zr-antibody PET is known to have a low SNR. To improve the diagnostic value of these scans, a Convolutional Neural Network (CNN) denoising method is proposed. The aim of this study was therefore to develop CNNs to increase SNR for low-count 18F-FDG and 89Zr-antibody PET. Super-low-count, low-count and full-count 18F-FDG PET scans from 60 primary lung cancer patients and full-count 89Zr-rituximab PET scans from five patients with non-Hodgkin lymphoma were acquired. CNNs were built to capture the features and to denoise the PET scans. Additionally, Gaussian smoothing (GS) and Bilateral filtering (BF) were evaluated. The performance of the denoising approaches was assessed based on the tumour recovery coefficient (TRC), coefficient of variance (COV; level of noise), and a qualitative assessment by two nuclear medicine physicians. The CNNs had a higher TRC and comparable or lower COV to GS and BF and was also the preferred method of the two observers for both 18F-FDG and 89Zr-rituximab PET. The CNNs improved the SNR of low-count 18F-FDG and 89Zr-rituximab PET, with almost similar or better clinical performance than the full-count PET, respectively. Additionally, the CNNs showed better performance than GS and BF.
Collapse
Affiliation(s)
- Bart M. de Vries
- Cancer Center Amsterdam, Department of Radiology and Nuclear Medicine, Vrije Universiteit Amsterdam, Amsterdam UMC, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands; (S.S.V.G.); (G.J.C.Z.); (O.S.H.); (Y.W.S.J.); (M.C.H.); (G.A.M.S.v.D.); (J.J.M.Z.-B.); (R.B.); (M.Y.)
- Correspondence: ; Tel.: +31-643628806
| | - Sandeep S. V. Golla
- Cancer Center Amsterdam, Department of Radiology and Nuclear Medicine, Vrije Universiteit Amsterdam, Amsterdam UMC, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands; (S.S.V.G.); (G.J.C.Z.); (O.S.H.); (Y.W.S.J.); (M.C.H.); (G.A.M.S.v.D.); (J.J.M.Z.-B.); (R.B.); (M.Y.)
| | - Gerben J. C. Zwezerijnen
- Cancer Center Amsterdam, Department of Radiology and Nuclear Medicine, Vrije Universiteit Amsterdam, Amsterdam UMC, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands; (S.S.V.G.); (G.J.C.Z.); (O.S.H.); (Y.W.S.J.); (M.C.H.); (G.A.M.S.v.D.); (J.J.M.Z.-B.); (R.B.); (M.Y.)
| | - Otto S. Hoekstra
- Cancer Center Amsterdam, Department of Radiology and Nuclear Medicine, Vrije Universiteit Amsterdam, Amsterdam UMC, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands; (S.S.V.G.); (G.J.C.Z.); (O.S.H.); (Y.W.S.J.); (M.C.H.); (G.A.M.S.v.D.); (J.J.M.Z.-B.); (R.B.); (M.Y.)
| | - Yvonne W. S. Jauw
- Cancer Center Amsterdam, Department of Radiology and Nuclear Medicine, Vrije Universiteit Amsterdam, Amsterdam UMC, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands; (S.S.V.G.); (G.J.C.Z.); (O.S.H.); (Y.W.S.J.); (M.C.H.); (G.A.M.S.v.D.); (J.J.M.Z.-B.); (R.B.); (M.Y.)
- Cancer Center Amsterdam, Department of Hematology, Vrije Universiteit Amsterdam, Amsterdam UMC, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
| | - Marc C. Huisman
- Cancer Center Amsterdam, Department of Radiology and Nuclear Medicine, Vrije Universiteit Amsterdam, Amsterdam UMC, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands; (S.S.V.G.); (G.J.C.Z.); (O.S.H.); (Y.W.S.J.); (M.C.H.); (G.A.M.S.v.D.); (J.J.M.Z.-B.); (R.B.); (M.Y.)
| | - Guus A. M. S. van Dongen
- Cancer Center Amsterdam, Department of Radiology and Nuclear Medicine, Vrije Universiteit Amsterdam, Amsterdam UMC, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands; (S.S.V.G.); (G.J.C.Z.); (O.S.H.); (Y.W.S.J.); (M.C.H.); (G.A.M.S.v.D.); (J.J.M.Z.-B.); (R.B.); (M.Y.)
| | | | - Josée J. M. Zijlstra-Baalbergen
- Cancer Center Amsterdam, Department of Radiology and Nuclear Medicine, Vrije Universiteit Amsterdam, Amsterdam UMC, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands; (S.S.V.G.); (G.J.C.Z.); (O.S.H.); (Y.W.S.J.); (M.C.H.); (G.A.M.S.v.D.); (J.J.M.Z.-B.); (R.B.); (M.Y.)
- Cancer Center Amsterdam, Department of Hematology, Vrije Universiteit Amsterdam, Amsterdam UMC, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
| | - Liesbet Mesotten
- Faculty of Medicine and Life Sciences, Hasselt University, Agoralaan Building D, B-3590 Diepenbeek, Belgium;
- Department of Nuclear Medicine, Ziekenhuis Oost Limburg, Schiepse Bos 6, B-3600 Genk, Belgium
| | - Ronald Boellaard
- Cancer Center Amsterdam, Department of Radiology and Nuclear Medicine, Vrije Universiteit Amsterdam, Amsterdam UMC, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands; (S.S.V.G.); (G.J.C.Z.); (O.S.H.); (Y.W.S.J.); (M.C.H.); (G.A.M.S.v.D.); (J.J.M.Z.-B.); (R.B.); (M.Y.)
| | - Maqsood Yaqub
- Cancer Center Amsterdam, Department of Radiology and Nuclear Medicine, Vrije Universiteit Amsterdam, Amsterdam UMC, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands; (S.S.V.G.); (G.J.C.Z.); (O.S.H.); (Y.W.S.J.); (M.C.H.); (G.A.M.S.v.D.); (J.J.M.Z.-B.); (R.B.); (M.Y.)
| |
Collapse
|